🟢 Roche is trading 3.89% up today after partner MediLink's positive Phase III TAISHAN-302 results

Roche is trading 3.89% up now at $54.80 after partner MediLink reported positive Phase III TAISHAN-302 results on September 13, 2026.

• Tam-Peli reduced mortality risk by 54% versus topotecan in relapsed small-cell lung cancer, strengthening Roche’s oncology pipeline and supporting plans for global trials.
• The company-specific catalyst is driving gains despite weaker major U.S. indexes and broader market caution.
• Healthcare’s defensive strength may provide additional support, but the MediLink announcement is the clearest explanation for Roche’s move.